Multiple Chinese ventures including Xianbo, MagicRNA, Siran and Leaderna secure new funding to push ahead with early- or mid-stage clinical studies for their novel assets.
Multiple Chinese ventures including Xianbo, MagicRNA, Siran and Leaderna secure new funding to push ahead with early- or mid-stage clinical studies for their novel assets.